Elahe Zaremoghadam

Elahe Zaremoghadam

Auto-generated profile, based on publicly available information

Elahe Zaremoghadam

Department of Internal Medicine, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Immunopathologia Persa
Verified
Journal Article
Open access
PDF file
EMElham Mohammadzadeh
Elham Mohammadzadeh
RARazieh Bagheri Shahzadeh Aliakbari
Razieh Bagheri Shahzadeh Aliakbari
ANAtieh Nouralishahi
Atieh Nouralishahi
AKAmin Khameneh
Amin Khameneh
BGBabak Gholamine
Babak Gholamine
EZElahe Zaremoghadam
Elahe Zaremoghadam
Introduction: Colorectal cancer (CRC) ranks as the third most prevalent diagnosed tumor worldwide. While the association between constipation and certain tumors has been established, our study aims to examine the relationship between constipation and colorectal tumors. Materials and Methods: This study employed a systematic review and meta-analysis following the PRISMA reporting guidelines. Searches were conducted without time restrictions until November 4, 2023, across various databases, including PubMed, Scopus, Web of Science, Cochrane, and the Google Scholar search engine. Data analysis was performed using STATA 14, and statistical significance was indicated by P<0.05. Results: This meta-analysis included 18 studies (9 cohort studies and 9 case-control studies) with a total sample size of 1,462,496 individuals. Overall, no significant association was found between constipation and colorectal tumors (OR: 1.09, 95% CI: 0.91–1.31), colon tumor (OR: 1.09, 95% CI: 0.89–1.34), and rectal tumor (OR: 0.95, 95% CI: 0.69–1.32). Subgroup analysis, however, revealed no statistically significant association between constipation and colorectal tumors (OR: 0.93, 95% CI: 0.76–1.14), colon tumors (OR: 0.92, 95% CI: 0.75–1.13), and rectal tumor (OR: 0.92, 95% CI: 0.65–1.21) in cohort studies. In case-control studies, constipation was associated with an increased risk of colorectal tumors (OR: 1.78, 95% CI: 1.12–2.83) and colon tumors (OR: 2.32, 95% CI: 1.58–3.42), while the association between constipation and rectal tumor in case-control studies was (OR: 1.40 (95% CI: 0.62, 2.89). Conclusion: In case-control studies, constipation emerged as a risk factor for colorectal and colon tumors, raising concerns given the high prevalence of constipation globally. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023481321) and Research Registry (UIN: reviewregistry1741) website.

29 July 2023 in Journal of Parathyroid Disease
Verified
Journal Article
Open access
PDF file
FKFariba Jafari Khabaz
Fariba Jafari Khabaz
EZElahe Zaremoghadam
Elahe Zaremoghadam
SASoleyman Alivand
Soleyman Alivand
NANoorbakhsh Alivand
Noorbakhsh Alivand
MHMahsa Asadollahi Hamedani
Mahsa Asadollahi Hamedani
MKMohamad Khaledi
Mohamad Khaledi
There is increasing evidence that vitamin D deficiency may contribute to hypertension. Low vitamin D levels are associated with an increased risk of high blood pressure, and studies have shown that vitamin D supplementation can help lower blood pressure. However, more research is needed to fully understand the mechanisms by which vitamin D regulates blood pressure and to determine the optimal dosage for supplementation. Nevertheless, ensuring adequate vitamin D levels through diet or supplements may be essential for preventing and managing hypertension.

5 February 2023 in Journal of Nephropathology
Verified
Journal Article
Open access
MMMobin Mohammadtabar
Mobin Mohammadtabar
AFAlireza Fazeli
Alireza Fazeli
NPNajmeh Parsai
Najmeh Parsai
ZAZahra Aboulfathiyarmohammadyar
Zahra Aboulfathiyarmohammadyar
ESErfan Shafiei
Erfan Shafiei
HMHossein Mardanparvar
Hossein Mardanparvar
Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the most recent pharmaceutical group for type 2 diabetes (T2D) treatment. Evidence indicates contradictory relationships between sodium-glucose cotransporter-2 inhibitors and bladder cancer (BC). Hence, this study aims to investigate the relationship between SGLT2 inhibitors and BC in patients with T2D. Materials and Methods: This study is a systematic review and meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). International databases including Cochrane, Web of Science, Scopus, PubMed, and Google Scholar were conducted for searching with keywords and without time and language limitations. The reference searching stage continued upgrading until November, 2022. Data analysis was performed with STATA 14 software. The tests with P values lower than 0.05 were considered statistically significant. Results: The four reviewed studies with a sample size comprising 497 755 individuals indicated the impact of SGLT2 inhibitors on BC of patients with T2D (OR: 0.68; 95% CI: 0.37, 1.2). The effect of dapagliflozin, canagliflozin and empagliflozin administration on the incidence of BC among the T2D patients were (OR: 0.72; 95% CI: 0.39, 1.30), (OR: 0.53; 95% CI: 0.23, 1.20), and (OR: 0.51; 95% CI: 0.20, 1.28), respectively. Conclusion: The general conclusion of this study revealed that SGLT2 inhibitors did not increase the risk of BC in T2D patients. The analysis of subgroups also indicated that the administration of dapagliflozin, canagliflozin, and empagliflozin also did not increase the risk of BC in T2D patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID=CRD42023389014).

29 July 2023 in Journal of Parathyroid Disease
Verified
Journal Article
Open access
PDF file
MSMaedeh Hamrah Siyani
Maedeh Hamrah Siyani
FZFaraz Zandiyeh
Faraz Zandiyeh
EZElahe Zaremoghadam
Elahe Zaremoghadam
SDSara Dehghan
Sara Dehghan
RSReyhaneh Sadeghian
Reyhaneh Sadeghian
MAMina Alipoor
Mina Alipoor
Parathyroid hormone (PTH) is a hormone produced by the parathyroid glands that regulates calcium and phosphate metabolism in the body. Magnesium is an essential mineral that plays a role in many cellular processes, including nerve and muscle function, DNA synthesis, and bone health. This review aims to examine the association between PTH and magnesium in health and disease states. Several studies have shown that lower levels of magnesium in the blood are associated with higher levels of PTH. This association has been observed in both healthy individuals and those with chronic kidney disease, primary hyperparathyroidism, and vitamin D deficiency. The mechanism by which magnesium regulates PTH synthesis is not yet fully understood but appears to involve magnesium’s role in the calcium-sensing receptor (CaSR) and cellular signaling pathways. In conclusion, the evidence suggests a clear and significant association between PTH and magnesium, with lower serum magnesium levels associated with elevated PTH levels. Further research is needed to understand clinical practice’s underlying mechanisms and implications.

7 December 2025 in Journal of Parathyroid Disease
Verified
Journal Article
Open access
Sina Salem AhimSina Salem Ahim
Sina Salem Ahim
SASara Aghaei
Sara Aghaei
FBFarzin Banei
Farzin Banei
MMMohammad Mousavi
Mohammad Mousavi
Mohammad ShahsavanMohammad Shahsavan
Mohammad Shahsavan
FNFaezeh Nesaei
Faezeh Nesaei
The brain-gut-bone axis plays a crucial and complex role in regulating bone metabolism, particularly in the context of osteoporosis. This multidirectional communication network integrates signals from several physiological systems, including the gut microbiota, immune system, nervous system, and hormonal environment, all of which collectively influence the balance between bone formation by osteoblasts and bone resorption by osteoclasts. The gut microbiota contributes to this axis by producing metabolites such as short-chain fatty acids (SCFAs) and modulating systemic inflammation, which in turn can affect bone cell activity and mineralization processes. The immune system participates through cytokine signaling that either promotes or inhibits bone resorption and formation, linking inflammation to bone health. Meanwhile, the nervous system, via autonomic and sensory pathways, regulates nutrient absorption, bone blood flow, and directly modulates bone cell function through neuropeptides and neurotransmitters. Hormonal factors, including parathyroid hormone, sex steroids, and gut-derived hormones like serotonin, further modulate bone turnover by fine-tuning osteoblast and osteoclast activity. Disruptions in any component of this axis, such as dysbiosis of the gut microbiota, chronic inflammation, neurotransmitter imbalance, or hormonal deficiencies can lead to dysregulated bone remodeling, favoring increased bone resorption, decreased bone formation, and eventually decreased bone density. This manifests clinically as osteoporosis, characterized by fragile bones and elevated fracture risk. Therefore, understanding and targeting the brain-gut-bone axis presents promising therapeutic opportunities. Interventions such as probiotics, anti-inflammatory therapies, neuromodulation, and hormone replacement can potentially restore the balance in this axis, improving bone health and reducing osteoporosis progression. This integrative approach highlights the importance of systemic interactions and opens new avenues for precision medicine in bone metabolic disorders.

19 October 2022 in Journal of Parathyroid Disease
Verified
Journal Article
Open access
PDF file
EZElahe Zaremoghadam
Elahe Zaremoghadam
EPEnsiye Pordel
Ensiye Pordel
MAMostafa Assarroudi
Mostafa Assarroudi
SMSaeid Mohammadi
Saeid Mohammadi
ASAli Kalali Sani
Ali Kalali Sani
SASara Abbasian
Sara Abbasian
Introduction: Thyroid status because of the expression of angiotensin-converting enzyme-2 (ACE2), which is a functional receptor for coronavirus disease 2019 (COVID-19) in thyroid glands, maybe affects COVID-19 patients’ outcomes. Objectives: This study aimed to evaluate the correlation of thyroid status with the severity and mortality of COVID-19 patients. Patients and Methods: In a retrospective cohort study conducted on 521 COVID-19 patients, data were collected by a demographic questionnaire and a checklist of patient outcomes (death/recovery) from the hospital information system (HIS) and analyzed by SPSS version 26 and binary logistic regression. Data about thyroid status were collected from clinical documents and laboratory test data. Results: Most patients were male (57.2%) with a mean age of 56.12 ± 17.4 years. Seventy-seven patients had a severe stage of disease, and 55 patients died. Twenty-one patients had hyperthyroidism, and 53 patients had hypothyroidism. Results showed that the correlation between hypothyroidism and hyperthyroidism with severity and mortality risk of COVID-19 patients was insignificant (P > 0.05). Conclusion: In this study, we concluded that, thyroid status is not associated with COVID-19 outcomes such as severity or mortality.